THE WOODLANDS, Texas, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that Joseph S. Podolski is leaving his position as President and Chief Executive Officer and member of the Board of Directors to pursue other interests. Larry Dillaha, M.D., Chief Executive Officer of CavtheRx, was appointed interim President and Chief Executive Officer of the Company, effective immediately.
“As Repros continues to advance its pipeline, the board will be conducting a search for a CEO with the appropriate experience to lead the Company’s next stage of growth,” said Patrick Fourteau, Chairman of the Company’s Board. “We’re grateful for Joe’s many years of dedication to Repros and wish him every success in his future endeavors.”
Prior to becoming CEO of CavtheRx, Dr. Dillaha was Chief Operating Officer and Chief Medical Officer of New Haven Pharmaceuticals, a specialty pharmaceutical company. He also served as Chief Medical Officer of Insys Therapeutics, Sciele Pharma and as Medical Director of Sanofi-Sythelabo. Dr. Dillaha received an M.D. degree from the University of Tennessee, Memphis.
About Repros Therapeutics Inc.®
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
